Biocon Receives FDA Approval for Generic Everolimus Tablets for Rare Neurological Disorder
核心洞察
Biocon Pharma Limited has received U.S. FDA approval for its generic everolimus tablets for oral suspension in 2 mg, 3 mg, and 5 mg strengths.
The medication is indicated for treating adult and pediatric patients aged 1 year and older with Tuberous Sclerosis Complex (搜索) who have Subependymal Giant Cell Astrocytoma (搜索).
The approval also covers adjunctive treatment of TSC-associated partial-onset seizures (搜索) in patients aged 2 years and older.
Biocon Pharma Limited, a wholly owned subsidiary of Biocon, has received approval from the U.S. Food and Drug Administration (搜索) for its Abbreviated New Drug Application (ANDA) for Everolimus Tablets for Oral Suspension. The approval covers three dosage strengths: 2 mg, 3 mg, and 5 mg, marking a significant expansion of the company's therapeutic offerings in rare neurological conditions.
Therapeutic Applications
The FDA-approved everolimus tablets are indicated for the treatment of adult and pediatric patients aged 1 year and older with Tuberous Sclerosis Complex (搜索) (TSC) who have Subependymal Giant Cell Astrocytoma (搜索) (SEGA). Additionally, the medication serves as an adjunctive treatment for adult and pediatric patients aged 2 years and older with TSC-associated partial-onset seizures (搜索).
Tuberous Sclerosis Complex (搜索) is a rare genetic disorder that causes non-malignant tumors to form in many different organs, primarily in the brain, eyes, heart, kidney, skin and lungs. SEGA represents one of the most serious neurological manifestations of TSC, requiring specialized therapeutic intervention.
Portfolio Impact
According to Biocon's company statement, the approval will further strengthen the company's portfolio of vertically integrated drug products. The FDA approval enables Biocon to address what the company describes as a significant unmet medical need, reinforcing its market position in specialized therapeutic areas.
The everolimus tablets for oral suspension formulation provides an important treatment option for both adult and pediatric populations affected by these rare conditions, with age-specific indications starting from as young as 1 year for SEGA treatment and 2 years for seizure management.